Previous close | 23.98 |
Open | 24.18 |
Bid | 24.54 x N/A |
Ask | 24.88 x N/A |
Day's range | 24.18 - 24.18 |
52-week range | 16.32 - 25.80 |
Volume | |
Avg. volume | 0 |
Market cap | N/A |
Beta (5Y monthly) | N/A |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | 16 Jul 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
Swedish Orphan Biovitrum AB (publ) (Sobi®) has successfully completed the inaugural issue of senior unsecured bonds of SEK 3 billion under its newly established MTN programme.
Sobi® today announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has issued a positive opinion recommending approval of efanesoctocog alfa, for the treatment and prevention of bleeds and perioperative prophylaxis in haemophilia A. Efanesoctocog alfa is a once-weekly and high-sustained factor VIII replacement therapy for patients of all ages and any disease severity.
Swedish Orphan Biovitrum AB (publ) (Sobi®) today announced its report for the first quarter 2024